BTK INHIBITOR COMBINATIONS FOR TREATING MULTIPLE MYELOMA

摘要

Disclosed herein are pharmaceutical combinations, dosing regimen, and methods of administering a combination of a BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, and a steroid for the treatment of a hematologic malignancy.